For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 100,640 | |||
| General and administrative | 21,411 | |||
| Total operating expenses | 122,051 | |||
| Loss from operations | -122,051 | |||
| Interest income | 16,630 | |||
| Other income (expense), net | -12 | |||
| Total other income, net | 16,618 | |||
| Net loss | -105,433 | |||
| Basic EPS | -1.85 | |||
| Diluted EPS | -1.85 | |||
| Basic Average Shares | 45,614,142 | |||
| Diluted Average Shares | 45,614,142 | |||
Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (ORKA)